


**Dated:** \_\_\_\_\_

Docket No.: 09857/0203535-US0  
(PATENT)



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Shigeru Akasofu et al.

Application No.: 10/560,179

Confirmation No.: N/A

Filed: December 9, 2005

Art Unit: N/A

For: NEUROCYTE PROTECTIVE AGENT

Examiner: Not Yet Assigned

## **SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed within three months of the date of entry of the national stage of an international application as set forth in 37 CFR 1.491 (37 CFR 1.97(b)(2)).

Applicant submits herewith copies of foreign and non-patents in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as


defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Commissioner is authorized to charge any deficiency of up to \$300.00 or credit any excess in this fee to Deposit Account No. 04-0100.

Dated: January 30, 2006

Respectfully submitted,

By  Flynn Baranow  
(53,970)

Jason C. Chumney

Registration No.: 54,781

DARBY & DARBY P.C.

P.O. Box 5257

New York, New York 10150-5257

(212) 527-7700

(212) 527-7701 (Fax)

Attorneys/Agents For Applicant



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Project of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/560,179	
			Filing Date	December 9, 2005	
			First Named Inventor	Shigeru Akasofu	
			Art Unit	N/A	
			Examiner Name	Not Yet Assigned	
Sheet	1	of	2	Attorney Docket Number	09857/0203535-USO


U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CA	"Protective effect of donepezil in a primary culture of rat cortical neurons exposed to oxygen-glucose deprivation", AKASOFU et al., European Journal of Pharmacology 472 (2003) pp. 57-63.	
	CB	"Huperzine B, a novel acetylcholinesterase inhibitor, attenuates hydrogen peroxide induced injury in PC12 cells", ZHANG et al., Neuroscience Letters 292 (2000), pp. 41-44.	
	CC	"Huperzine A and donepezil protect rat pheochromocytoma cells against oxygen-glucose deprivation", ZHOU et al., Neuroscience Letters 306 (2001) pp. 53-56.	
	CD	"Acetylcholinesterase Promotes the Aggregation of Amyloid- $\beta$ -Peptide Fragments by Forming a Complex with the Growing Fibrils", ALVAREZ et al., J. Mol. Biol. (1997) 272, pp. 348-361.	
	CE	" $\beta$ -Amyloid aggregation induced by human acetylcholinesterase: inhibition studies", BARTOLINI et al., Biochemical Pharmacology 65 (2003), pp. 407-416.	
	CF	"Increased expression of intranuclear AChE involved in apoptosis of SK-N-SH cells", YANG et al., Neuroscience Research 42 (2002), pp. 261-268.	
	CG	"Cerebro-protective effects of ENA713, a novel acetylcholinesterase inhibitor, in closed head injury in the rat", CHEN et al., Brain Research 784 (1998), pp. 18-24.	
	CH	"Protection against ischemic injury in primary cultured astrocytes of mouse cerebral cortex by bis(7)-tacrine, a novel anti-Alzheimer's agent", HAN et al., Neuroscience Letters 288 (2000), pp. 95-98.	
	CI	"Tacrine and donepezil attenuate the neurotoxic effect of A $\beta$ (25-35) in rat PC12 cells", SVENSSON et al., NeuroReport 9, 1519-1522 (1998), pp. 1519-1522.	
	CJ	"Nicotinic Acetylcholine Receptor-Mediated Neuroprotection by Donepezil Against Glutamate Neurotoxicity in Rat Cortical Neurons", TAKADA et al., The Journal of Pharmacology and Experimental Therapeutic, Vol. 306, No. 2, 2003, pp. 772-777.	
	CK	"Randomized, Placebo-Controlled Trial of the Effects of Donepezil on Neuronal Markers and Hippocampal Volumes in Alzheimer's Disease", KRISHNAN, et al., Am. J. Psychiatry 2003, 160, pp. 2003-2011.	
	CL	"3-(40[(Benzyl(methyl)amino)methyl]-phenyl)-6, 7-dimethoxy-2H-2-chromenone (AP2238) Inhibits Both Acetylcholinesterase and Acetylcholinesterase-Induced $\beta$ -Amyloid Aggregation:	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Project (PTO/SB/08a/b), no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/560,179
				Filing Date	December 9, 2005
				First Named Inventor	Shigeru Akasofu
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	09857/0203535-USO

		A Dual Function Lead for Alzheimer's Disease Therapy", PIAZZI et al., J. Med. Chem. 2003, 46, pp. 2279-2282.	
	CM	"Stable Complexes Involving Acetylcholinesterase and Amyloid- $\beta$ Peptide Change the Biochemical Properties of the Enzyme and Increase the Neurotoxicity of Alzheimer's Fibrils", ALVAREZ et al., The Journal of Neuroscience, May 1, 1998, 18(9), pp. 3213-3223.	
	CN	"Acetylcholinesterase induces neuronal cell loss, astrocyte hypertrophy and behavioral deficits in mammalian hippocampus", CHACON et al., Journal of Neurochemistry, 2003, 87, pp. 195-204.	
	CO	"Antisense oligonucleotide inhibition of acetylcholinesterase gene expression induces progenitor cell expansion and suppresses hematopoietic apoptosis, <i>ex vivo</i> ", SOREQ et al., Proc. Natl. Acad. Sci. USA, Vol. 91, pp. 7907-7911, August 1994.	
	CP	"Induction of acetylcholinesterase expression during apoptosis in various cell types", ZHANG et al., Cell Death and Differentiation (2002) 9, pp. 790-800.	
	CQ	"Huperzine A attenuates hydrogen peroxide-induced apoptosis by regulating expression of apoptosis-related genes in rat PC12 cells", WANG et al., Neuropharmacology and Neurotoxicology, Vol. 12, No. 12, August 28, 2001, pp. 2629-2634.	
	CR	"Use of Donepezil for Vascular Dementia: Preliminary Clinical Experience", MENDEZ et al., Clinical and Research Report, J. Neuropsychiatry Clin Neurosci 11: 2, Spring 1999, pp. 268-270.	


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Application No. (if known): 10/560,179

Attorney Docket No.: 09857/0203535-US0



## Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. \_\_\_\_\_ in an envelope addressed to:

**EV778822462-US**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

on January 30, 2006  
Date

  
Signature

D B Beck  
Typed or printed name of person signing Certificate

Registration Number, if applicable \_\_\_\_\_

Telephone Number \_\_\_\_\_

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Supplemental Information Disclosure Statement (2 pp)  
PTO/SB/08A (2 pp) w/18 documents  
Return Receipt Postcard